NCT03673020 is a Phase 1 clinical trial of ASV® AGEN2017 + QS-21 Stimulon® adjuvant in Solid Tumor, Adult, sponsored by Agenus Inc..

Who is sponsoring NCT03673020?

NCT03673020 is sponsored by Agenus Inc..

What drugs are being tested in NCT03673020?

Interventions in NCT03673020: ASV® AGEN2017 + QS-21 Stimulon® adjuvant.

What condition does NCT03673020 study?

NCT03673020 studies Solid Tumor, Adult.

Is NCT03673020 still recruiting?

NCT03673020 is currently completed. Last updated 2 December 2021.

Last reviewed 2021-12-02 · How we verify

NCT03673020

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1a Study to Evaluate Immunogenicity of ASV®

Completed Phase 1 Last updated 2 December 2021

What this trial tests

Phase 1 trial testing ASV® AGEN2017 + QS-21 Stimulon® adjuvant in Solid Tumor, Adult in 3 participants. Completed in 3 February 2021.

Timeline

16 May 2019

Primary endpoint
3 February 2021

3 February 2021

Quick facts

Lead sponsor	Agenus Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	16 May 2019
Primary completion	3 February 2021
Estimated completion	3 February 2021
Sites	1 location across United States

Drugs / interventions tested

ASV® AGEN2017 + QS-21 Stimulon® adjuvant — full drug profile →

Conditions studied

Solid Tumor, Adult — all drugs for Solid Tumor, Adult →

Sponsor

Agenus Inc. — full company profile →

Who can join

18 and older, any sex, with Solid Tumor, Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label Phase 1a First-in-Human Study to determine Safety and Tolerability of ASV® AGEN2017 with QS-21 Stimulon® Adjuvant as a Single Agent in Subjects With Tumors at Risk of Relapse Undergoing Observation as Standard of Care Following Complete Surgical Resection.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Neoantigens: promising targets for cancer therapy.
Xie N, Shen G, Gao W, Huang Z, et al · · 2023 · cited 713× · PMID 36604431 · DOI 10.1038/s41392-022-01270-x
Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities.
Shemesh CS, Hsu JC, Hosseini I, Shen BQ, et al · · 2021 · cited 187× · PMID 33038322 · DOI 10.1016/j.ymthe.2020.09.038
Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group.
De Mattos-Arruda L, Vazquez M, Finotello F, Lepore R, et al · · 2020 · cited 126× · PMID 32610166 · DOI 10.1016/j.annonc.2020.05.008
Mutation-Derived Neoantigens for Cancer Immunotherapy.
Castle JC, Uduman M, Pabla S, Stein RB, et al · · 2019 · cited 92× · PMID 31440245 · DOI 10.3389/fimmu.2019.01856
Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.
Chen X, Yang J, Wang L, Liu B. · · 2020 · cited 69× · PMID 32483434 · DOI 10.7150/thno.38742
Designing neoantigen cancer vaccines, trials, and outcomes.
Biswas N, Chakrabarti S, Padul V, Jones LD, et al · · 2023 · cited 43× · PMID 36845151 · DOI 10.3389/fimmu.2023.1105420
Neoantigen Vaccines; Clinical Trials, Classes, Indications, Adjuvants and Combinatorial Treatments.
Niemi JVL, Sokolov AV, Schiöth HB. · · 2022 · cited 42× · PMID 36291947 · DOI 10.3390/cancers14205163
Neoantigen cancer vaccines: a new star on the horizon.
Li X, You J, Hong L, Liu W, et al · · 2023 · cited 31× · PMID 38164734 · DOI 10.20892/j.issn.2095-3941.2023.0395

Verify or expand the search:

Other recruiting trials for Solid Tumor, Adult

Currently open trials in the same condition.

NCT07139990 — Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) · Phase 1 · recruiting
NCT06398418 — R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients · Phase 1 · recruiting
NCT06682793 — A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor · Phase 1, PHASE2 · recruiting
NCT07137195 — Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei) · NA · active not recruiting
NCT06714617 — Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting

Other Agenus Inc. trials

Trials by the same sponsor.

NCT05630183 — A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer · Phase 2 · active not recruiting
NCT05377528 — Study of AGEN1571 in Participants With Advanced Solid Tumors · Phase 1 · completed
NCT05025085 — A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors · Phase 1 · completed
NCT05033132 — A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer · Phase 2 · withdrawn
NCT04943627 — Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) · Phase 3 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03673020 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Agenus Inc.
Last refreshed: 2 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03673020.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing